Next Article in Journal
Computer-Assisted Discovery of Alkaloids with Schistosomicidal Activity
Next Article in Special Issue
Single Circulating-Tumor-Cell-Targeted Sequencing to Identify Somatic Variants in Liquid Biopsies in Non-Small-Cell Lung Cancer Patients
Previous Article in Journal / Special Issue
Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

Personalized 3-Gene Panel for Prostate Cancer Target Therapy

Department of Pathology, New York Medical College, Valhalla, NY 10595, USA
Personalized Genomics Laboratory, Center for Computational Systems Biology, Roy G. Perry College of Engineering, Prairie View A&M University, Prairie View, TX 77446, USA
Author to whom correspondence should be addressed.
Academic Editor: Arumugam R. Jayakumar
Curr. Issues Mol. Biol. 2022, 44(1), 360-382;
Received: 18 November 2021 / Revised: 5 January 2022 / Accepted: 11 January 2022 / Published: 15 January 2022
(This article belongs to the Special Issue Molecules at Play in Cancer)
Many years and billions spent for research did not yet produce an effective answer to prostate cancer (PCa). Not only each human, but even each cancer nodule in the same tumor, has unique transcriptome topology. The differences go beyond the expression level to the expression control and networking of individual genes. The unrepeatable heterogeneous transcriptomic organization among men makes the quest for universal biomarkers and “fit-for-all” treatments unrealistic. We present a bioinformatics procedure to identify each patient’s unique triplet of PCa Gene Master Regulators (GMRs) and predict consequences of their experimental manipulation. The procedure is based on the Genomic Fabric Paradigm (GFP), which characterizes each individual gene by the independent expression level, expression variability and expression coordination with each other gene. GFP can identify the GMRs whose controlled alteration would selectively kill the cancer cells with little consequence on the normal tissue. The method was applied to microarray data on surgically removed prostates from two men with metastatic PCas (each with three distinct cancer nodules), and DU145 and LNCaP PCa cell lines. The applications verified that each PCa case is unique and predicted the consequences of the GMRs’ manipulation. The predictions are theoretical and need further experimental validation. View Full-Text
Keywords: AP5M1; BAIAP2L1; CRISPR; ENTPD2; master regulator; LOC145474; MTOR; PRRG1; VIM; WFDC3 AP5M1; BAIAP2L1; CRISPR; ENTPD2; master regulator; LOC145474; MTOR; PRRG1; VIM; WFDC3
Show Figures

Figure 1

MDPI and ACS Style

Iacobas, S.; Iacobas, D.A. Personalized 3-Gene Panel for Prostate Cancer Target Therapy. Curr. Issues Mol. Biol. 2022, 44, 360-382.

AMA Style

Iacobas S, Iacobas DA. Personalized 3-Gene Panel for Prostate Cancer Target Therapy. Current Issues in Molecular Biology. 2022; 44(1):360-382.

Chicago/Turabian Style

Iacobas, Sanda, and Dumitru A. Iacobas. 2022. "Personalized 3-Gene Panel for Prostate Cancer Target Therapy" Current Issues in Molecular Biology 44, no. 1: 360-382.

Find Other Styles

Article Access Map by Country/Region

Back to TopTop